Barely Significant
← all excerpts

Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with <i>ROS1+</i> NSCLC.

Cancers (Basel) · 2025 · PMC11899369 · PMID 40075596

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
crizotinib) and in DoR (entrectinib only, due to non-reporting for crizotinib) showed a trend toward more favorable outcomes with repotrectinib.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.